Alpha-Mannosidosis Epidemiology

Alpha-mannosidosis Insights and Trends

• Alpha-mannosidosis is an ultra-rare, progressive lysosomal storage disorder caused by pathogenic variants in the MAN2B1 gene, leading to deficiency of the lysosomal enzyme alpha-mannosidase and subsequent accumulation of mannose-rich oligosaccharides in multiple tissues. The disease is characterized by a broad spectrum of manifestations, including intellectual disability, hearing impairment, skeletal abnormalities, immune dysfunction, motor impairment, and progressive neurological decline.
• In the United states, the prevalence of alpha-mannosidosis is estimated to be 1 in every 500,000 people in the general population. 
• The clinical burden of alpha-mannosidosis is becoming increasingly apparent as advances in genetic testing, enzyme activity assays, and physician awareness improve disease recognition and diagnosis. Expanded access to molecular diagnostics has facilitated earlier and more accurate identification of affected individuals, reducing historical diagnostic delays. 

DelveInsight’s “Alpha-mannosidosis Epidemiology, Forecast – 2036” report delivers an in depth understanding of alpha-mannosidosis historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered

North America: The United States 

Europe: Germany, France, Italy, and Spain and the United Kingdom

Asia-Pacific: Japan

Alpha-mannosidosis Understanding

Alpha-mannosidosis Overview and Diagnosis

Alpha-mannosidosis is a rare inherited lysosomal storage disorder caused by mutations in the MAN2B1 gene, leading to a deficiency of the enzyme alpha-D-mannosidase. This enzyme deficiency results in the accumulation of mannose-rich oligosaccharides in cells, causing progressive damage to multiple organs and tissues. The disease follows an autosomal recessive inheritance pattern and exists along a clinical spectrum ranging from mild (Type 1) to severe (Type 3), with most patients presenting with the moderate form (Type 2). Key manifestations include recurrent infections due to immune deficiency, skeletal abnormalities, hearing loss, cognitive and speech impairment, psychiatric symptoms, and motor dysfunction such as muscle weakness, joint problems, and ataxia. 

The diagnostic workup for alpha-mannosidosis begins with clinical suspicion based on key features — intellectual disability, skeletal abnormalities, hearing loss, and recurrent infections. Initial screening involves urine or serum oligosaccharide analysis, followed by enzymatic measurement of acid alpha-mannosidase activity in leukocytes as the gold-standard confirmatory step. Molecular testing of the MAN2B1 gene serves as the final confirmatory step, enabling carrier detection in relatives and antenatal diagnosis using both biochemical and genetic methods.

Further details related to country-based variations are provided in the report…

Alpha-mannosidosis Epidemiology

Key Findings from Alpha-mannosidosis Epidemiological Analysis and Forecast

• As per secondary analysis, the prevalence of alpha-mannosidosis is estimated to be 1 in every 500,000 people in the general population. 
• Alpha-mannosidosis affects males and females in equal numbers and can potentially affect individuals of any ethnic group worldwide.
• Based on secondary data analysis, the estimated prevalence of alpha-mannosidosis in Italy ranges from approximately 1 in 250,000 to 1 in 1 million live births, underscoring its classification as an ultra-rare lysosomal storage disorder within the national population.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of alpha-mannosidosis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Alpha-mannosidosis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 

FAQs

• What are the disease risks, burdens, and unmet needs of alpha-mannosidosis? 
• What will be the growth opportunities across the 7MM concerning the patient population with alpha-mannosidosis?
• What is the alpha-mannosidosis prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted alpha-mannosidosis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on alpha-mannosidosis burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the alpha-mannosidosis epidemiology analysis and patient population trends.